Merck cough drug doesn’t pass panel scrutiny
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Category: Pharmaceuticals
STAT+: U.K., pharma industry strike deal for how the NHS pays for medicines
LONDON — The U.K. and the pharmaceutical industry have reached a deal on a five-year…
STAT+: What Eli Lilly’s Zepbound reveals about the intricate process of naming drugs today
Whether you’re a fan of the drug name Zepbound or, like one X user, think…
The return of biotech’s “bump factor” amid an economic downturn
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Even as Wegovy rides high, interest surges in weight loss drugs that preserve muscle
Have you ever seen a mouse with a set of muscles more appropriate for a…
STAT+: FDA’s Janet Woodcock to retire early next year
WASHINGTON — Principal Deputy FDA Commissioner Janet Woodcock will retire early next year from the…
STAT+: FDA cites Dr. Reddy’s for quality control problems at a biologics plant
Dr. Reddy’s Laboratories, one of the world’s largest generic drugmakers, was cited by the U.S….
How do we know Alzheimer’s drugs ‘work’?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
.jpg)
STAT+: More drug and device patents were invalidated for bad info than those filed by other industries, analysis finds
The patents on medicines and devices approved by the U.S. Food and Drug Administration were…
STAT+: FDA’s latest reorganization puts a new emphasis on its investigations
WASHINGTON — There’s about to be a new acronym in town. The Food and Drug…
The apparently strong correlation between biotech stocks and the price of eggs, explained
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: To get things done fast at FDA: ‘Don’t tell anybody,’ cancer chief says
WASHINGTON — The Food and Drug Administration’s top cancer drug regulator doesn’t always ask for…
STAT+: New NIH head says government has fallen behind pharma on clinical trials
WASHINGTON — The new National Institutes of Health director, Monica Bertagnolli, said it’s a “failure”…
What health policies could hitch a ride on a spending bill?
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
AMA urges coverage of obesity treatments as payers balk at costs
WASHINGTON – The American Medical Association called on insurance companies, employers, and government programs to…
STAT+: Michigan bill that would pare back pharma liability shied law moves closer to enactment
A one-of-a-kind law in Michigan that prevents the state government and residents from suing pharmaceutical…
Novo Nordisk has its sights on becoming a major player in heart disease
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Eli Lilly’s chief scientist on new obesity drug data, gene editing, and a potential new heart drug
PHILADELPHIA — In a sense, the annual meeting of the American Heart Association wasn’t a…
Wegovy cuts risk of heart attacks in milestone cardiovascular trial
PHILADELPHIA — Novo Nordisk’s obesity drug Wegovy notably cut the risk of heart attacks in…
The first vaccine for the increasingly prevalent chikungunya virus is here
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: EU regulator recommends expanding diabetes drug Mounjaro’s approval to include obesity
LONDON — Two days after similar decisions in the U.S. and U.K., regulators in Europe…
Eli Lilly tries a rare tactic: competing on price
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Senate panel clears PBM reforms, safety-net hospital payments
WASHINGTON — A prominent Senate panel on Wednesday passed a new package of health policy…
STAT+: Sanofi CEO defends company’s move to abandon profit guidance and boost research
LONDON — Sanofi CEO Paul Hudson on Wednesday defended his company’s recent moves to abandon…
BioMarin’s new CEO inherits a profitable company, a pioneering gene therapy, and a brewing activist challenge
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: In the fight against cancer, it’s boom times for radiopharmaceuticals
When Ken Song was getting ready to leave his job as the CEO of a…
STAT+: FTC challenges several big drugmakers over inaccurate or improper patent listings
Making good on a recent threat, the U.S. Federal Trade Commission is challenging more than…
Your morning biotech news roundup
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Vertex may face another battle in the U.K. over the value of its cystic fibrosis medicines
Once again, Vertex Pharmaceuticals and a U.K. government agency are at odds over the value…
Shrinking COVID vaccine sales has Moderna course-correcting
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Health plan formularies lowered barriers to fair access to some drugs, analysis finds
Most of the formularies run by some of the largest health plans in the U.S….
Novo Nordisk is concluding research on Wegovy’s impact on osteoarthritis
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Nostrum Laboratories and its CEO — who once defended Shkreli price hikes — to pay up to $50 million over Medicaid rebates
A pharmaceutical company and its chief executive — who once defended Martin Shkreli for raising…
STAT+: Pharmalittle: Panel tells FDA that CRISPR sickle cell therapy is safe enough for patients; U.K. is urged to scrap IP demands in trade talks with India
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
Opinion: Listen: Sniffing out the power, and limits, of the placebo effect
Have you ever taken phenylephrine for a stuffed-up nose and then felt better? If so,…
STAT+: Medicare is urged to consider Amgen patent maneuvers when negotiating the price for a drug
As Medicare prepares to negotiate prices for its first batch of medicines, an advocacy group…
Sarepta’s disappointing data put the FDA in a difficult spot
Want to stay on top of the science and politics driving biotech today? Sign up to get…
.jpg)
STAT+: Tracking the FDA advisory panel on the first CRISPR-based treatment for sickle cell disease
The Food and Drug Administration is convening a meeting of outside experts on Tuesday to…
Your Monday morning biotech news roundup
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: An exit interview with Bristol Myers Squibb CEO Giovanni Caforio
It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO…
Senate committee plans Nov. 8 vote on wide-ranging health care package
WASHINGTON — The Senate Finance Committee plans to vote Nov. 8 on legislation that includes…
STAT+: Why Sanofi got shellacked
Sanofi, the Paris-based drug giant, announced Friday that it would spin out its $5 billion…
Regeneron gene therapy improves hearing in child
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Sanofi plans to spin off its consumer health biz; EMA says no evidence GLP-1 drugs linked to thyroid cancer
And so, another working week will soon draw to a close. Not a moment too…
Pfizer’s twice daily pill for obesity hopes to rival Wegovy and Mounjaro
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Under-the-skin injection of Eisai’s Leqembi is as effective as IV infusion, new Alzheimer’s data show
A version of the Alzheimer’s disease drug Leqembi that can be given with a simpler,…
STAT+: Europe takes steps to head off drug shortages, even as U.S. proposals stall
European drug regulators are updating regulations to stem drug shortages. Are there lessons for Americans?…
STAT+: Novartis claims Takeda is stonewalling efforts to review trade secrets taken by a former employee
Novartis has gone to court to gain access to Takeda Pharmaceutical documents over concerns that…
The XBI biotech index hit its lowest point since 2018. No one knows what comes next.
Want to stay on top of the science and politics driving biotech today? Sign up to get…